skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
We are delighted to announce the shortlist for the 14th Annual Scrip Awards.

Over the summer, our panel of 17 respected judges has reviewed all the entries to produce a shortlist that displays the wealth of innovation, dedication and hard work that the  pharmaceutical and biotech industries have shown over the past year.

Please see the full shortlist below or click here to view a PDF.

Best Company in an Emerging Market

Beximco Pharmaceuticals


CinnaGen Pharmaceutical Group

Hutchison China MediTech (Chi-Med)

Mundipharma Singapore

WuXi Biologics


Best Contract Research Organization – Full-Service Providers

CMIC Group





Worldwide Clinical Trials


Best Contract Research Organization – Specialist Providers


Illingworth Research Group




Tioga Research


Best Technological Development in Clinical Trials - Clinical Sponsor-focused

Cytel’s OK GO software

Novartis’s Nerve Live

Covance’s Xcellerate CRA Dashboard

PAREXEL’s Perceptive Cloud

IQVIA’s Mobile SVR application



Best Technological Development in Clinical Trials - Tech Sponsor-focused

Phesi’s real-time data collection and analysis

CluePoints’ Intelligent Central Statistical Monitoring Solution

Bioclinica’s Bioclinica Clinical Adjudication

ERT’s Advanced Imaging Technology Solution

Ergomed/PrimeVigilance/Automation Anywhere’s robotic process automation software

Medidata’s Medidata Rave Engage


Community Partnership of the Year AwardSponsored by Medidata Solutions

AstraZeneca’s Mentoring Team

Beximco Pharma with DSM Nutritional Products and Sight & Life Global Nutrition Research Institute to improve nutrition in rural Bangladesh

IQVIA India’s Race for 7 with the Organization for Rare Diseases India

Oxford PharmaGenesis’ Open Pharma


Best Use of Real-World Evidence

Biogen/ICON’s New insights into the burden and costs of multiple sclerosis in Europe

ICON/Vertex’s study of lumacaftor/ivacaftor lung function decline in patients with cystic fibrosis

ICON’s Transthyretin Amyloidosis Outcomes Survey (THAOS)

IQVIA/Bristol-Myers Squibb’s I-O Optimise collaboration in patients with a thoracic malignancy

PAREXEL International's Multiple Sclerosis Algorithms Development and Validation project

Neurocrine BioSciences’s RE-KINECT prospective real-world dyskinesia screening study and registry in patients taking antipsychotics


Best Partnership Alliance

Bicycle Therapeutics and Bioverativ for hemophilia and sickle cell disease using bi-cyclic peptides

Evotec and Sanofi's strategic collaboration to establish a new open innovation platform

F-star and Denali Therapeutics to develop a multi-specific platform for delivery of medicines across the blood-brain barrier

Neurocrine and AbbVie for elagolix in women’s health

Roche and Ionis Pharmaceuticals to develop antisense drugs for Huntington's disease

Novartis and the University of Pennsylvania for CAR-T medications in pediatric cancer patients


Financing Deal of the Year – Public

InflaRx’s $100m IPO and secondary offering

resTORbio’s $163m Series A to IPO

Polyphor’s CHF165m IPO

Horizon Discovery Group’s £80m public placing

Ablynx’s $200m US IPO on NASDAQ

Morphosys’ $239m overallotment issue and NASDAQ listing


Financing Deal of the Year – Private

Crescendo Biologics' $70m Series B financing

Enterprise Therapeutics’ £29m ($41m) Series B financing

BioNTech’s $270m Series A financing

AstraZeneca/MedImmune’s $250m financing for spin-out Viela Bio

PhoreMost’s £11m ($15m) Series A financing

NodThera’s £28m Series A financing


IQVIA’s Clinical Advance of the Year Award

Ablynx’s Phase III HERCULES study of caplacizumab for acquired thrombotic thrombocytopenic purpura

Alexion Pharmaceuticals' Phase III REGAIN study of Soliris (eculizumab) in myasthenia gravis

bluebird bio’s Northstar-2 study of LentiGlobin in beta-thalassemia

GW Pharmaceuticals’ Phase III GWPCARE4 trial of Epidiolex for refractory epilepsy

Ipca Laboratories Phase IV study of hydroxychloroquine in type 2 diabetes mellitus in India

Nanobiotix’s Phase I/II trial of nanomedicine NBTXR3 in head and neck cancer


Licensing Deal of the YearSponsored by Worldwide Clinical Trials

AiCuris and Merck & Co (MSD) for Prevymis (letermovir) for cytomegalovirus

AstraZeneca and Merck & Co (MSD) for Lynparza and selumetinib

AstraZeneca and Pearl Therapeutics for PT027 in asthma

Emergent BioSolutions and Valneva for the Zika vaccine candidate VLA1601

F-star (through F-star Delta) and Merck KGaA for five bispecific antibodies in immuno-oncology

Halozyme and Bristol-Myers Squibb for the use of ENHANZE drug delivery technology in immuno-oncology drugs


Executive of the Year – For Large & Medium Cap Companies

Edwin Moses, CEO of Ablynx

John Maraganore, CEO of Alnylam

Alan Hirzel, CEO of Abcam

Jan van de Winkle, CEO of Genmab

Vas Narasimhan, CEO of Novartis

Niels Riedemann, CEO co-founder of InflaRx


Executive of the Year – For Small Cap & Private Pharma Companies

Eduardo Bravo, CEO of TiGenix

Jurgi Camblong, CEO and founder of SOPHiA GENETICS

Carl Firth, CEO and founder of ASLAN Pharmaceuticals

Antony Loebel, executive vice president, chief medical officer, head of global clinical development of Sunovion Pharmaceuticals

Amy Schulman, CEO and co-founder of Lyndra

Raman Singh, CEO of Mundipharma Singapore


WuXi AppTec’s Biotech Company of the Year Award




Neurocrine Biosciences

Bicycle Therapeutics

Diurnal Group


Business Development Team of the Year

AstraZeneca and Avillion partnership team

Bicycle Therapeutics’ business development team

CinnaGen’s business development team

Evotec’s business development team

F-star’s business development team

Rentschler Biopharma/Leukocare alliance business development team


Syneos Health's Best New Drug Award

TiGenix’s Alofisel (darvadstrocel)

Roche’s Hemlibra (emicizumab)

Novartis’s Kymriah (tisagenlecleucel)

Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl)

Kite Pharma/Gilead Sciences’ Yescarta (axicabtagene ciloleucel)

Scrip Awards 2018

Scrip Awards 2018

For Sponsorship inquiries:

Christopher Keeling
Tel: +44 (20) 337 73183
Mobile: +44 (0) 7917 647 859

For all other inquiries:

Natalia Kay
Tel: +44 (0) 20 7017 5173
Mobile +44 (0) 7917 265 637